Patients with HER2-positive breast cancer are normally treated with a combination of two or more chemotherapy drugs and targeted agents which block the HER2 receptor, followed by surgery, radiotherapy and sometimes hormonal therapies. Here, ERBB2 is linked to breast carcinoma.